1. Home
  2. AIDX vs MIRA Comparison

AIDX vs MIRA Comparison

Compare AIDX & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIDX

20/20 Biolabs Inc. Common Stock

N/A

Current Price

$1.92

Market Cap

58.8M

Sector

Health Care

ML Signal

N/A

Logo MIRA Pharmaceuticals Inc.

MIRA

MIRA Pharmaceuticals Inc.

HOLD

Current Price

$1.00

Market Cap

53.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIDX
MIRA
Founded
N/A
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Precision Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.8M
53.2M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
AIDX
MIRA
Price
$1.92
$1.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
280.5K
124.8K
Earning Date
N/A
03-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
20.31
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.87
$0.81
52 Week High
$14.09
$2.45

Technical Indicators

Market Signals
Indicator
AIDX
MIRA
Relative Strength Index (RSI) 4.91 28.75
Support Level N/A N/A
Resistance Level $3.08 $1.35
Average True Range (ATR) 0.44 0.08
MACD 0.02 -0.01
Stochastic Oscillator 7.05 6.45

Price Performance

Historical Comparison
AIDX
MIRA

About AIDX 20/20 Biolabs Inc. Common Stock

20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.

About MIRA MIRA Pharmaceuticals Inc.

Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.

Share on Social Networks: